Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (190${count})

  • Research Grant, 2015
    Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement

    Study Rationale:                   
    STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in...

  • Research Grant, 2014
    Role of LRRK2 in Dopamine Modulation of Striatal Glutamate Transmission

    Objective/Rationale: 
    Many of the motor symptoms in Parkinson’s disease (PD) are attributed to a deficit of the neurotransmitter dopamine in the brain region called the striatum. Recent studies show...

  • Dyskinesia Challenge, 2012
    Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia

    Objective/Rationale:
    Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky movements caused by long-term use of the Parkinson’s drug levodopa...

  • Summer 2022 RFP: The Edmond J. Safra Movement Disorders Research Career Development Award, 2022
    Tracking Eye Movements and Pupil Responses as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders

    Study Rationale: We do not currently have accurate tests to diagnose Parkinson’s disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage. Similarly, we do not have...

  • Research Resources, 2022
    Neural Network Imaging Analysis in Parkinson’s Disease Associated with Parkin Mutation

    Study Rationale: Clinical imaging biomarkers are desperately needed to provide a non-invasive means of assessing therapeutic efficacy in clinical trials for Parkinson’s disease (PD). Recent studies...

  • Target Advancement Program, 2021
    Sex-based Modulation of Neuromelanin-linked Parkinson’s Disease Pathology

    Study Rationale:
    Parkinson’s disease (PD) is more common in men than in women, and men with PD exhibit earlier onset, faster progression, more severe motor symptoms and more frequent cognitive decline...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.